Novo Nordisk’s Pill Push: EU Approval and Factory Expansion Target the Needle?Averse, But Price Pain Persists
Published on 07/16/2026 at 18:24 | Redaktion boerse-global.de
Novo Nordisk’s stock has clawed back nearly 20% over the past month to trade at €44.99, a rally that reflects both the long?awaited EU green light for its oral Wegovy and a buyback programme that has already scooped up 6.5?billion Danish kroner of B?shares. Yet beneath the surface, the Danish drugmaker is juggling two opposing forces: a strategic pivot from injectables to tablets that demands enormous production capacity, and a pricing squeeze that management itself describes as “painful.”
The European Commission on 15?July?2026 approved the 25?mg once?daily Wegovy tablet alongside a new 7.2?mg single?dose injection pen. The oral formulation – the same semaglutide molecule that made the injectable version a blockbuster – targets the roughly 22% of overweight adults who avoid GLP?1 therapies because of injection anxiety. In the US, where the tablet has been available longer, it already commands 89% of new oral prescriptions, dwarfing Eli Lilly’s Foundayo at just 11%. Clinical data from the OASIS?4 study showed a mean weight loss of 17% with the 25?mg pill; one in three patients lost at least 20%.
Capturing that European opportunity, however, requires manufacturing muscle that few peers can match. Novo Nordisk is pouring €432?million into its Athlone, Ireland, site to add tablet?pressing capacity dedicated to oral semaglutide. The facility will serve every market outside the US, with production ramping up in phases between 2027 and 2028. Meanwhile, the company’s recently acquired plant in Bohumil, Czech Republic – where it invested roughly $360?million – has already started producing supporting proteins for the next generation of diabetes and obesity treatments. About 300 workers now staff the Czech site, which was taken over and modernised in late?2024.
The dual?location build?out is a clear signal that Novo Nordisk intends to exploit its regulatory head start before rivals can close the gap. Eli Lilly’s oral candidate, Retatrutide, has posted up to 28% weight loss in clinical trials – a data point that investors cannot ignore. Even so, Novo Nordisk’s ability to produce at scale today gives it a time buffer that competitors still need to build.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
That buffer is critical because the near?term outlook for profits is hardly rosy. Management expects both sales and earnings to contract by 13%, a forecast CEO Maziar Mike Doustdar has not shied away from calling “painful.” The main culprit is the “most?favoured?nation” agreement in the US, which is set to trim the monthly cost of Wegovy from $350 to $250. That pricing hit coincides with a Medicare GLP?1 expansion that came into effect on 1?July?2026, now covering an estimated 40?million Americans on these drugs. While volume expansion from the European pill launch could offset some of the pressure, the arithmetic remains tight.
Technically, the stock’s 14?day relative strength index sits at 70.5, just inside overbought territory. The current price of €44.99 represents a 47.8% rebound from the year’s low of €30.25 set in March, but it is still 26.6% below the 52?week high of €60.95. The 50?day moving average of €39.92 offers a near?term support level; a clean break below that could signal the good news is already discounted.
To shore up confidence, the board authorised a 12?month buyback programme worth 15?billion Danish kroner, with nearly half already completed by mid?July. The buyback, combined with the EU approval and the factory expansions, paints a picture of a company betting aggressively that its own pipeline and production scale will outrun the margin erosion.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The next concrete test will come in the second half of 2026 with the first sales data from the oral Wegovy rollout in major European markets. Beyond that, all eyes are on CagriSema – the combination therapy that could define Novo Nordisk’s next growth cycle. For now, the stock is caught between a promising pill and a hard price reality.
Ad
Novo Nordisk Stock: New Analysis - 16 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
